ArticleInnate immunity2022

Delayed inflammation decrease is associated with mortality in Tocilizumab-treated critically ill SARS-CoV-2 patients: A retrospective matched-cohort analysis.

Tomas Urbina et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.